Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 35 cents a share - Earnings Preview

Reviva Pharmaceuticals Holdings

26/03/2024 12:38

* Reviva Pharmaceuticals Holdings, Inc.  RVPH.OQ 
 RVPH.O  is
expected to show no change in quarterly revenue when it reports 
results on March 28 (estimated) for the period ending December
31 2023
    * 
    * ​LSEG's mean analyst estimate for Reviva Pharmaceuticals
Holdings, Inc. is for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reviva
Pharmaceuticals Holdings, Inc. is $17.00​, above​ its last
closing price of $3.14. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.43       -0.37      -0.44     Missed  -20.2
 Jun. 30 2023  -0.31       -0.28      -0.55     Missed  -99.3
 Mar. 31 2023  -0.32       -0.32      -0.30     Beat    7.7​
 Dec. 31 2022  -0.19       -0.22      -0.38     Missed  -72.7
 ​​Sep.        -0.28       -0.29      -0.18     Beat    37.2
 30 2022                                                
 Jun. 30 2022  -0.36       -0.35      -0.29     Beat    17.1​
 Mar. 31 2022  -0.28       -0.28      -0.40     Missed  -42.9
 Dec. 31 2021  -0.25       -0.25      -0.22     Beat    12
 This summary was machine generated March 26 at 12:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)